Compare DigitalOcean Holdings Inc (DOCN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DigitalOcean Holdings Inc vs Sanofi SA — how do they compare? DigitalOcean Holdings Inc trades at $133.78 (market cap $14.21B), while Sanofi SA trades at $43.76 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 7.3× DigitalOcean Holdings Inc's market cap, and Sanofi SA pays a 5.55% dividend while DigitalOcean Holdings Inc pays none. Which is the better fit depends on your goals.
| DOCN | SNY | |
|---|---|---|
Market Cap | $14.21B | $104.30B |
Sector | Technology | Health |
52-Week High | $181.29 | $52.34 |
52-Week Low | $29.99 | $41.33 |
Enterprise Value | $14.97B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DigitalOcean (DOCN) trades at $133.03, up 2.54% today, with a bearish technical signal but strong fundamental momentum. Recent Q2 2026 earnings beat expectations with 29% revenue growth, driven by AI-native cloud demand. The stock shows high valuation ratios (P/E 54.94, P/S 13.62) and robust profitability (net margin 23.27%, ROE 62.27%). Analyst consensus is bullish with a $173.71 price target, though technical indicators suggest near-term resistance at $134.
Outlook is positive due to accelerating AI-driven growth and raised 2027 guidance, but risks include high debt levels and valuation concerns. The stock offers upside if execution continues, yet volatility near resistance may prompt consolidation. Investors should weigh strong earnings against technical bearishness and leverage exposure.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
